The new AI-based application will help medical laboratory scientists and technicians to invest more time on advanced analysis. Credit: PRNewswire / Becton, Dickinson and Company.

Becton, Dickinson and Company (BD) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its new artificial intelligence (AI)-powered software to diagnose Methicillin-resistant Staphylococcus aureus (MRSA).

Using AI, the new BD Kiestra MRSA imaging application analyses bacterial growth and releases negative specimens with minimal human interaction. It helps in improving the efficiency and workflow of the microbiology laboratory.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The BD Kiestra is designed to automate the traditional labour-intensive and time-consuming process of examining Petri dishes to check bacterial growth.

It will help medical laboratory scientists and technicians to focus on advanced analysis.

BD Diagnostics general manager and vice-president Nikos Pavlidis said: “The pandemic created significant and ongoing labour challenges in laboratories and reading plates is a labour-intense, potentially error-prone process in microbiology.

See Also:

“The use of this imaging application to automatically organise specimens in meaningful worklists helps use limited laboratory staff more efficiently and allows lab personnel to bring their expertise to bear on more critical and complex specimens.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The application helps assess individual specimens or consolidate a significant number of plates exhibiting insignificant growth for batch review and release of negative results to lower the administrative workload on technicians.

It utilises AI algorithms to identify specific culture characteristics on the BBL CHROMagar MRSA II plate.

Plate images can be automatically organised and arranged into meaningful worklists for laboratory scientists and technicians with the help of the information and analysis provided by BD Synapsys informatics.

The AI-based imaging application used the BD Synapsys Informatics Solution and is supported by the BD BBL CHROMagar MRSA II screening plates.

It is compatible with both the standalone BD Kiestra ReadA systems and the track-based BD Kiestra laboratory automation solutions.